Clinical Trials Logo

Clinical Trial Summary

Wild-type transthyretin cardiac amyloidosis (ATTRwt) is a deposition disorder in which one of the proteins of the body misfolds and accumulates at various places in the body, including the heart, leading to both mechanical and cellular damage. The gradual development of the disease will ultimately lead to heart failure and death The protein which deposits in the heart of patients, damages both the heart mechanically as the myocardium becomes rigid and hypertrophic over time but also at the cellular level. Cell damage can be observed by elevated blood tests for cell damage (Troponin) and during exercise tests that show patients' hearts burning oxygen inefficiently when exposed to physical stress compared with the hearts of healthy individuals . No one has, however, intimately studied this cellular damage. Vastarel® (Trimetazidine, TMZ) is an already known drug for the treatment of chest pain. The mechanism of action indicates that it may have an effect on patients with cardiac amyloidosis. The study aims to investigate the effects of TMZ on the mitochondrial function, myocardial performance, and invasive hemodynamics in patients with ATTRwt with a randomized, double-blinded, crossover-trial.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05633563
Study type Interventional
Source Aarhus University Hospital Skejby
Contact
Status Completed
Phase Phase 4
Start date October 1, 2021
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT03704311 - Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry N/A
Completed NCT03344913 - Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis N/A
Not yet recruiting NCT04379934 - Functional and Metabolic Effects of Ketone Bodies on Human Atrial Tissue in Patients With and Without Heart Failure N/A
Not yet recruiting NCT04322734 - Transgenerational Metabolic-Immune Biomarkers of Neurological and Neurodevelopmental Disorders
Active, not recruiting NCT05162768 - Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) Phase 3